Meridian Bioscience (VIVO) Akcija Kursas

Meridian Bioscience Kursas

NASDAQ·UŽDARTAS
3,08
​
Rinka uždaryta

Per pastaruosius 19 metus Meridian Bioscience pajamos augo 8,9 % kasmet ir pasiekė 333,02 mln. USD. Pelnas akcijai augo 8,4 % per metus per pastaruosius 19 metus. Meridian Bioscience grynoji marža 12,7 % yra išaugo palyginti su 11,1 % prieš kelerius metus. Esama kaina dividendo pajamingumas yra apie 4,06 %. Išmokų koeficientas yra apie 22 % pelno.

Meridian Bioscience akcijos kaina

Gaukite šiuos duomenis per Eulerpool API

100 000 užklausų/mėn. nemokamai · be kortelės

Meridian Bioscience akcija ir akcijų analizė

„Meridian Bioscience Inc.“ yra pasaulinė įmonė, specializuojasi infekcinių ligų ir kitų medicinos būklių diagnostikai skirtų testavimo rinkinių kūrimo, gamybos ir platinimo srityse. Įmonė buvo įkurta 1976 m. Williamo J. Motto ir iš pradžių koncentravosi į fermentinio imuninio sorbcijos testo (EIA) vystymą. Per metus įmonė išsiplėtė ir įvairino savo produktų asortimentą, tapdama vienu pagrindinių ūmių ir lėtinių medicinos būklių, infekcinių ligų, virškinamojo trakto infekcijų bei virologijos diagnostikos testų tiekėjų. Įmonės sėkmę lemia įvairūs testai skirtingose medicinos srityse, įskaitant imunologiją, infekcines ligas, lytiškai plintančias ligas, gastroenterologiją ir virologiją. Be to, „Meridian Bioscience Inc.“ nuolat seka naujausias biotechnologijų technologines inovacijas, kad užtikrintų greitą ir efektyvų savo testų veikimą. Įmonė veikia globaliai, bendradarbiauja su universitetais, moksliniais tyrimų institutais, valstybinėmis agentūromis ir platintojais, siekdama užtikrinti savo produktų pasiekiamumą ir rinkodarą visame pasaulyje. Apibendrinant, „Meridian Bioscience Inc.“ yra novatoriška įmonė, specializuojasi infekcinių ligų ir kitų medicinos būklių diagnostikai skirtų testų kūrimo, gamybos ir platinimo srityse. Jos platus produktų spektras, apimantis imunologijos produktus, infekcinių ligų diagnostiką, lytiškai plintančių ligų testus, gastroenterologiją, virologiją ir molekulinę diagnostiką, kartu su pažangiomis technologijomis, suteikia greitą, tikslią ir patikrą diagnostinę paramą.

Dažnai užduodami klausimai apie Meridian Bioscience akciją

The business model of Meridian Bioscience Inc revolves around manufacturing and distributing diagnostic products for the healthcare industry. With a focus on infectious disease testing, the company provides a range of products including molecular and immunoassay tests, as well as reagents and related equipment. Meridian Bioscience Inc aims to develop innovative solutions for quick and accurate diagnosis, helping healthcare professionals worldwide make informed decisions. Through its expertise and continual investment in research and development, the company strives to improve patient outcomes and contribute to the overall public health. Meridian Bioscience Inc's commitment to quality and customer satisfaction is evident in their comprehensive portfolio of diagnostic solutions.

Meridian Bioscience Inc is primarily active in the healthcare and life sciences industries.

The main competitors of Meridian Bioscience Inc in the market are companies like Thermo Fisher Scientific, BD (Becton, Dickinson and Company), Quidel Corporation, and Bio-Rad Laboratories. These companies operate in the healthcare and diagnostics industry, offering similar products and services. Meridian Bioscience Inc competes based on factors such as product quality, technological advancements, pricing strategy, and customer satisfaction. While Thermo Fisher Scientific is a well-established player in the market, Meridian Bioscience Inc continues to carve its niche through innovative solutions and a strong customer-centric approach.

Meridian Bioscience Inc is a leading life science company that develops and markets a broad range of innovative diagnostic products. Founded in 1976, the company has a rich history and a strong background in developing and commercializing diagnostic tests for various infectious diseases. Meridian Bioscience Inc has evolved over the years and has expanded its product portfolio to cater to the needs of laboratories, hospitals, and other healthcare providers worldwide. With a focus on quality, accuracy, and reliability, the company has garnered a reputation for delivering efficient and effective diagnostic solutions. Meridian Bioscience Inc remains committed to advancing healthcare and improving patient outcomes through its cutting-edge diagnostic technologies and dedication to innovation.

Meridian Bioscience Inc has achieved several significant milestones throughout its history. One notable accomplishment is the company's development and commercialization of innovative diagnostic test kits for various diseases and healthcare conditions. Furthermore, Meridian Bioscience Inc has consistently expanded its product portfolio, introducing novel technologies to improve healthcare outcomes. The company's dedication to research and development has led to the successful launch of multiple FDA-cleared and CE-marked diagnostic tests. Meridian Bioscience Inc's commitment to quality has enabled it to establish a strong presence in the global diagnostics market.

Meridian Bioscience Inc is primarily present in the United States.

Meridian Bioscience Inc represents a strong set of values and corporate philosophy. The company is committed to quality and innovation in the field of biotechnology. They strive to provide accurate and reliable diagnostic solutions to improve patient care. Meridian Bioscience Inc also prioritizes integrity and ethical conduct in all aspects of their business operations. With a focus on customer satisfaction, they aim to exceed expectations and deliver exceptional products and services. As an industry leader, Meridian Bioscience Inc continues to drive advancements in the healthcare sector through their dedication to excellence and integrity.

7 analitikai šiuo metu vertina Meridian Bioscience akciją: 6 rekomenduoja pirkti, 1 laikyti ir 0 parduoti.

Pagal dabartinį kursą Meridian Bioscience akcija kainuoja 2,74 EUR (3,08 USD).

Meridian Bioscience akcija (VIVO) kotiruojama 4 biržose, įskaitant: NASDAQ (VIVO), London (0K0K.L), Frankfurt (MR4.F), München (MR4.MU).

Meridian Bioscience Inc is a global company specializing in the development, manufacture, and distribution of diagnostic and testing systems for the rapid and accurate identification of infectious diseases. The company was founded in 1976 and is headquartered in Cincinnati, Ohio. Meridian Bioscience operates several business segments, including diagnostics, OEM, and life science. In the diagnostics segment, the company offers a variety of products for the identification of infectious diseases, including tests for respiratory infections, gastroenteritis, STDs, and Zika virus. Meridian Bioscience's diagnostic products are used in clinical laboratories, hospitals, medical practices, and research laboratories worldwide. The OEM segment of Meridian Bioscience offers customized diagnostic products tailored to the specific requirements of OEM customers. This includes both raw materials and finished products that can be integrated into customers' diagnostic products. The OEM segment of Meridian Bioscience works closely with OEM customers to provide customized, cost-effective, and high-quality products. In the life science segment, Meridian Bioscience offers a wide range of products, including enzymes, antibodies, proteins, buffering solutions, and labeling reagents. These products are used in research and development, diagnostics, and industry. Meridian Bioscience has experienced strong growth in recent years, driven by the introduction of new products, expansion into new markets, and the acquisition of other companies. An example of this is the acquisition of the Bioline Group in 2018, a leading provider of molecular biology products used in research and diagnostics. Meridian Bioscience is committed to developing and manufacturing high-quality products that deliver fast and accurate results. The company works closely with customers and partners to develop innovative products that meet the needs of the healthcare industry. With its wide range of products and commitment to innovation and quality, Meridian Bioscience will continue to play an important role in the diagnostics industry.

Pelnas šiuo metu negali būti apskaičiuotas Meridian Bioscience.

Pelnas šiuo metu negali būti apskaičiuotas Meridian Bioscience.

KGV šiuo metu negali būti apskaičiuotas Meridian Bioscience.

KUV šiuo metu negali būti apskaičiuotas Meridian Bioscience.

Eulerpool kokybės balas Meridian Bioscience yra 6/10.

Meridian Bioscience ISIN yra US5895841014. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.

Meridian Bioscience WKN yra 871583. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.

Meridian Bioscience prekybos žymė yra VIVO. Ši biržos žymė naudojama Meridian Bioscience akcijoms prekiauti biržoje.

Tikroji vertėTerminal
2,86 USD
Per/Nepakankamai vertintaTerminal
Teisingai vertinta
Sektorius
Industrija
Sveikatos priežiūros įranga ir pasiūla
Akcijų skaičius
Darbuotojai
Pajamos vienam darbuotojui
504 572,73 USD
Pajamų augimas Ø5 metai
EBIT augimas Ø5 metai
Grynojo pelno augimas Ø5 metai
Valiuta
USD
Pirminis viešas pasiūlymas
1986-07-29
ISIN
US5895841014
CUSIP
589584101
SEDOL
2580265
Rinkos kapitalizacija
52 savaičių diapazonas
AAQS
7 / 10
PEG
—
P/E santykis
K/P santykise 2023
3,66
K/P santykise 2024
5,21
K/P santykise 2025
7,28
P/S
K/A santykise
0,46
EV/EBIT
—
P/B santykis
0,37
ROE (nuosavo kapitalo grąža)
ROA (turto grąža)
ROCE (grąža iš panaudoto kapitalo)
ROIC (grąža iš investuoto kapitalo)
10,80 %
Paskutinį kartą atnaujinta 2026-10-22 14:07

Meridian Bioscience Biržos simbolis

FRANKFURTAS · MR4.FLONDON · 0K0K.LMIUNCHENAS · MR4.MUNASDAQ · VIVO

Meridian Bioscience FIGI

MR4:GF · BBG000GT3TJ1MR4:GS · BBG000GT4YY2VIVOUSD:XB · BBG00JSL7CZ9VIVOUSD:XS · BBG00JSL7DF9VIVOGBX:B1 · BBG00L2YZQT9